Momcozy Brings Experts and Mothers Together to Celebrate Breastfeeding Month in the Philippines
Momcozy marks its first-ever brand event in the Philippines with Breathe & Breastfeed! MANILA, Philippines, Aug. 21, 2026 /PRNewswire/ -- In celebration of Breastfeeding Month, Momcozy held its first-ever brand event in the Philippines, bringing healthcare professionals, breastfeeding advocates and mothers together for Breathe & Breastfeed: Support for Every Latch, Letdown, and Little Win. Momcozy APAC Marketing Director Ellen...
China’s Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a “DeepSeek Moment”?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed attention to clinical development and translational progress in China. Among the companies advancing in this field, Beijing-based Likang Life Sciences...
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World’s First Approved 4-1BB-Targeting Therapy
NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Opamtistomig (LBL-024), the Company's proprietary PD-L1/4-1BB bispecific antibody, as a monotherapy for the treatment of previously...
Colgate-Palmolive elevates Prabha Narasimhan to EVP – Marketing, Asia-Pacific
MUMBAI, India, Aug. 21, 2026 /PRNewswire/ -- Prabha Narasimhan, Managing Director and Chief Executive Officer of Colgate-Palmolive (India) Limited has been elevated to the role of Executive Vice President – Marketing, Asia-Pacific Division, Colgate-Palmolive, effective close of business hours on 27 September, 2026. Prabha Narasimhan elevated to APAC role...
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZEGFROVY® (sunvozertinib) in non-small cell lung cancer (NSCLC) will be...
3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company reached RMB 1.15 billion, and adjusted operating net profit attributable to shareholders of...
Akeso’s AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant...
Sunshine Guojian Releases 2026 Interim Report:
Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the first half of 2026, Sunshine Guojian pursued its dual-engine strategy of "In-house R&D plus External Collaboration", drove growth through innovation, delivered...
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution Conference Call Scheduled: August 21 at 8:30 a.m. HKT DURHAM, N.C. and BEIJING, Aug. 21, 2026 /PRNewswire/ -- Brii...
Angel Yeast’s AHH Packaging Design Recognized with Red Dot Award
SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Angel Nutritech, a professional yeast biotechnology subsidiary under Angel Yeast (SSE: 600298), has been recognized for its Angel Human Health (AHH) yeast essence packaging design with a Red Dot Award: Brands & Communication Design 2026. Design Inspired by Scientific Rigor and Modern...
